NEW YORK (GenomeWeb News) – Response Biomedical this week said that it has consolidated its stock on a 10 for one basis. The Vancouver, BC-based molecular diagnostics company said that the consolidation applies to all of its common shares, stock options, and warrants. Following the consolidation, Response Biomedical has 25,467,200 common shares outstanding.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.